^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NI-2601
i
Other names: NI-2601, NI 2601, NI2601
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Light Chain Biosci
Drug class:
PD-L1 inhibitor, CD47 inhibitor
Related drugs:
over2years
NI-2601, an Fc-active CD47xPD-L1 bispecific antibody that selectively targets CD47 on PD-L1-positive tumors (AACR 2022)
The latter is also used in our CD47xCD19 bispecific antibody NI-1701/TG-1801, currently in phase I clinical trials (NCT03804996, NCT04806035)...NI-2601 demonstrated effective blockade of PD-1/PD-L1 interaction, and T-cell activation in vitro, similar to the anti-PD-L1 clinical benchmarks atezolizumab and avelumab...Thus, NI-2601 is able to harness Fc-effector function to eliminate PD-L1-positive tumor cells while sparing PD-L1-negative cells, such as RBC or platelets. Pharmacokinetic and tolerability studies in non-human primate are planned for 2022.
PD(L)-1 Biomarker • IO biomarker
|
CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
|
PD-L1 expression • PD-L1 negative
|
Tecentriq (atezolizumab) • Bavencio (avelumab) • NI-2601 • TG-1801
Share via
